In Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states, a paper in Brain by researchers led from the St Louis University Medical School, scientists document their work in switching off neural pain pathways by activating an adenosine receptor.
The technique doesn't rely on opiod-receptors, decreasing the likelihood that people who receive this treatment will become addicted to the treatment.
In this research, Salvemini and colleagues have demonstrated that activation of the A3 adenosine receptor subtype is key in mediating the pain relieving effects of adenosine.
"It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain," Salvemini said. "Our findings suggest that this goal may be achieved by focusing future work on the A3AR pathway, in particular, as its activation provides robust pain reduction across several types of pain."
Researchers are excited to note that A3AR agonists are already in advanced clinical trials as anti-inflammatory and anticancer agents and show good safety profiles. "These studies suggest that A3AR activation by highly selective small molecular weight A3AR agonists such as MRS5698 activates a pain-reducing pathway supporting the idea that we could develop A3AR agonists as possible new therapeutics to treat chronic pain," Salvemini said.
(Thumbnail: Open single-pole single-throw (SPST) knife switch, Ayl, CC-BY-SA)